OBJECTIVE: To analyze the occurrence and the functional effects of nonsynonymous single nucleotide polymorphisms in the human diamine oxidase (ABP1) gene. METHODS: Genomic DNA from 134 healthy Caucasian individuals was analyzed for three nonsynonymous single nucleotide polymorphisms in the ABP1 gene. Serum diamine oxidase activity was studied in 37 individuals with known ABP1 genotype. RESULTS: Variant ABP1 alleles leading to the amino-acid substitutions Thr16Met, Ser332Phe and His645Asp were identified with frequencies of 25.4, 6.3 and 30.6%, respectively. Over 70% of the population (95% confidence interval, 62.4-77.9%) carry at least one amino-acid substitution. Each amino-acid substitution was at Hardy-Weinberg's equilibrium, but linkage disequilibrium between variant alleles was observed. The percentage of individuals carrying simultaneously the three amino-acid substitutions in heterozygosity or homozygosity (9%, 95% confidence interval, 4.2-13.8%) was over three times that expected from a random association (P<0.05). Individuals carrying the 645Asp amino acid displayed lower serum diamine oxidase activity as compared with noncarriers (P<0.001) with a significant gene-dose effect (P<0.05). This was due to an increase in the Michaelis-Menten constant. Individuals heterozygous for 645Asp show Vmax/Km values of 66% and homozygous 51% as compared with noncarriers. The effect of the 16Met variant allele was lower and that of the rarest allele 332Phe was negligible. CONCLUSION: Nonsynonymous ABP1 gene polymorphisms are common in humans; they cause relevant functional effects and can be considered as major determinants of variability for human diamine oxidase activity.
OBJECTIVE: To analyze the occurrence and the functional effects of nonsynonymous single nucleotide polymorphisms in the humandiamine oxidase (ABP1) gene. METHODS: Genomic DNA from 134 healthy Caucasian individuals was analyzed for three nonsynonymous single nucleotide polymorphisms in the ABP1 gene. Serum diamine oxidase activity was studied in 37 individuals with known ABP1 genotype. RESULTS: Variant ABP1 alleles leading to the amino-acid substitutions Thr16Met, Ser332Phe and His645Asp were identified with frequencies of 25.4, 6.3 and 30.6%, respectively. Over 70% of the population (95% confidence interval, 62.4-77.9%) carry at least one amino-acid substitution. Each amino-acid substitution was at Hardy-Weinberg's equilibrium, but linkage disequilibrium between variant alleles was observed. The percentage of individuals carrying simultaneously the three amino-acid substitutions in heterozygosity or homozygosity (9%, 95% confidence interval, 4.2-13.8%) was over three times that expected from a random association (P<0.05). Individuals carrying the 645Asp amino acid displayed lower serum diamine oxidase activity as compared with noncarriers (P<0.001) with a significant gene-dose effect (P<0.05). This was due to an increase in the Michaelis-Menten constant. Individuals heterozygous for 645Asp show Vmax/Km values of 66% and homozygous 51% as compared with noncarriers. The effect of the 16Met variant allele was lower and that of the rarest allele 332Phe was negligible. CONCLUSION: Nonsynonymous ABP1 gene polymorphisms are common in humans; they cause relevant functional effects and can be considered as major determinants of variability for humandiamine oxidase activity.
Authors: Joan Izquierdo-Casas; Oriol Comas-Basté; M Luz Latorre-Moratalla; Marian Lorente-Gascón; Adriana Duelo; M Carmen Vidal-Carou; Luis Soler-Singla Journal: J Physiol Biochem Date: 2017-06-17 Impact factor: 4.158
Authors: José A G Agúndez; Antonio Luengo; Oscar Herráez; Carmen Martínez; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez; Elena García-Martín Journal: Neuromolecular Med Date: 2007-11-06 Impact factor: 3.843
Authors: Gemma Amo; José A Cornejo-García; Jesus M García-Menaya; Concepcion Cordobes; M J Torres; Gara Esguevillas; Cristobalina Mayorga; Carmen Martinez; Natalia Blanca-Lopez; Gabriela Canto; Alfonso Ramos; Miguel Blanca; José A G Agúndez; Elena García-Martín Journal: Front Pharmacol Date: 2016-09-29 Impact factor: 5.810
Authors: José A G Agúndez; Silvia Selinski; Emanuela Corsini; Klaus Golka; Elena García-Martín Journal: Front Pharmacol Date: 2017-06-07 Impact factor: 5.810
Authors: Bridgette L Jones; Catherine M T Sherwin; Xiaoxi Liu; Hongying Dai; Carrie A Vyhlidal Journal: Front Pharmacol Date: 2017-01-04 Impact factor: 5.810
Authors: Oriol Comas-Basté; Sònia Sánchez-Pérez; Maria Teresa Veciana-Nogués; Mariluz Latorre-Moratalla; María Del Carmen Vidal-Carou Journal: Biomolecules Date: 2020-08-14
Authors: José A G Agúndez; Pedro Ayuso; José A Cornejo-García; Miguel Blanca; María J Torres; Inmaculada Doña; María Salas; Natalia Blanca-López; Gabriela Canto; Carmen Rondon; Paloma Campo; José J Laguna; Javier Fernández; Carmen Martínez; Elena García-Martín Journal: PLoS One Date: 2012-11-12 Impact factor: 3.240